Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 290

1.

Late-onset common cancers in a kindred with an Arg213Gln TP53 germline mutation.

Ruijs MW, Verhoef S, Wigbout G, Pruntel R, Floore AN, de Jong D, van T Veer LJ, Menko FH.

Fam Cancer. 2006;5(2):169-74.

PMID:
16736287
2.

TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.

Ruijs MW, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst FB, Kluijt I, Sijmons RH, Aalfs CM, Wagner A, Ausems MG, Hoogerbrugge N, van Asperen CJ, Gomez Garcia EB, Meijers-Heijboer H, Ten Kate LP, Menko FH, van 't Veer LJ.

J Med Genet. 2010 Jun;47(6):421-8. doi: 10.1136/jmg.2009.073429.

PMID:
20522432
3.

Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families.

Arcand SL, Maugard CM, Ghadirian P, Robidoux A, Perret C, Zhang P, Fafard E, Mes-Masson AM, Foulkes WD, Provencher D, Narod SA, Tonin PN.

Breast Cancer Res Treat. 2008 Apr;108(3):399-408. Epub 2007 May 31.

PMID:
17541742
4.

Two TP53 germline mutations in a classical Li-Fraumeni syndrome family.

van Hest LP, Ruijs MW, Wagner A, van der Meer CA, Verhoef S, van't Veer LJ, Meijers-Heijboer H.

Fam Cancer. 2007;6(3):311-6. Epub 2007 Feb 23.

PMID:
17318340
5.

Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil.

Palmero EI, Schüler-Faccini L, Caleffi M, Achatz MI, Olivier M, Martel-Planche G, Marcel V, Aguiar E, Giacomazzi J, Ewald IP, Giugliani R, Hainaut P, Ashton-Prolla P.

Cancer Lett. 2008 Mar 8;261(1):21-5. doi: 10.1016/j.canlet.2007.10.044. Epub 2008 Jan 11.

PMID:
18248785
6.

Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation.

Salmon A, Amikam D, Sodha N, Davidson S, Basel-Vanagaite L, Eeles RA, Abeliovich D, Peretz T.

Clin Oncol (R Coll Radiol). 2007 Sep;19(7):490-3. Epub 2007 Jun 14.

PMID:
17572079
7.

The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes.

Ruijs MW, Schmidt MK, Nevanlinna H, Tommiska J, Aittomäki K, Pruntel R, Verhoef S, Van't Veer LJ.

Eur J Hum Genet. 2007 Jan;15(1):110-4. Epub 2006 Sep 27.

8.

Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family.

Evans SC, Mims B, McMasters KM, Foster CJ, deAndrade M, Amos CI, Strong LC, Lozano G.

Hum Genet. 1998 Jun;102(6):681-6.

PMID:
9703430
9.

Relative frequency and morphology of cancers in carriers of germline TP53 mutations.

Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, Eden OB, Varley JM.

Oncogene. 2001 Aug 2;20(34):4621-8.

10.

High frequency of de novo mutations in Li-Fraumeni syndrome.

Gonzalez KD, Buzin CH, Noltner KA, Gu D, Li W, Malkin D, Sommer SS.

J Med Genet. 2009 Oct;46(10):689-93. doi: 10.1136/jmg.2008.058958. Epub 2009 Jun 25.

PMID:
19556618
11.

Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.

Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA.

Cancer Res. 2003 Oct 15;63(20):6643-50.

12.

TP53 germline mutations in Portugal and genetic modifiers of age at cancer onset.

Pinto C, Veiga I, Pinheiro M, Peixoto A, Pinto A, Lopes JM, Reis RM, Oliveira C, Baptista M, Roque L, Regateiro F, Cirnes L, Hofstra RM, Seruca R, Castedo S, Teixeira MR.

Fam Cancer. 2009;8(4):383-90. doi: 10.1007/s10689-009-9251-y. Epub 2009 May 26.

PMID:
19468865
13.

Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.

Nichols KE, Malkin D, Garber JE, Fraumeni JF Jr, Li FP.

Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):83-7.

14.

The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.

Achatz MI, Olivier M, Le Calvez F, Martel-Planche G, Lopes A, Rossi BM, Ashton-Prolla P, Giugliani R, Palmero EI, Vargas FR, Da Rocha JC, Vettore AL, Hainaut P.

Cancer Lett. 2007 Jan 8;245(1-2):96-102. Epub 2006 Feb 21.

PMID:
16494995
15.

Germline TP53 mutations and Li-Fraumeni syndrome.

Varley JM.

Hum Mutat. 2003 Mar;21(3):313-20. Review. Erratum in: Hum Mutat. 2003 May;21(5):551.

PMID:
12619118
16.

Telomere length in peripheral blood cells of germline TP53 mutation carriers is shorter than that of normal individuals of corresponding age.

Trkova M, Prochazkova K, Krutilkova V, Sumerauer D, Sedlacek Z.

Cancer. 2007 Aug 1;110(3):694-702.

17.

The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.

Finkova A, Vazna A, Hrachovina O, Bendova S, Prochazkova K, Sedlacek Z.

Cancer Genet Cytogenet. 2009 Aug;193(1):63-6. doi: 10.1016/j.cancergencyto.2009.04.014.

PMID:
19602465
18.

[When is it useful to look for TP53 germline gene mutations in families of oncology patients?].

Trková M, Sedlácek Z.

Cas Lek Cesk. 2003;142(4):220-5. Czech.

PMID:
12841124
19.

High frequency of germline p53 mutations in childhood adrenocortical cancer.

Wagner J, Portwine C, Rabin K, Leclerc JM, Narod SA, Malkin D.

J Natl Cancer Inst. 1994 Nov 16;86(22):1707-10.

PMID:
7966399
20.

Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.

Birch JM, Blair V, Kelsey AM, Evans DG, Harris M, Tricker KJ, Varley JM.

Oncogene. 1998 Sep 3;17(9):1061-8.

Items per page

Supplemental Content

Write to the Help Desk